Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Clara Ventin"'
Autor:
Belén Atienza-Mateo, Esteban Rubio Romero, Ricardo Blanco, Miguel A. González-Gay, Luis Fernández-Dominguez, B. Joven-Ibáñez, Beatriz Arca, Alfonso Corrales, Clara Ventin-Rodriguez, José Luis Martín-Varillas, Jose Campos Esteban, Antia Crespo Golmar, Francisco Ortiz-Sanjuán, Maria Jose Moreno, Manuel Moreno, Eva Galindez, O. Maíz, Rafael Melero, Agusti Sellas-Fernández, Raul Veroz Gonzalez, Enrique Raya, Roberto Daniel Gonzalez Benitez, Olga Rusinovich, Alejandro Escudero Contreras, Emma Beltrán, Vanesa Calvo-Río, Natalia Palmou-Fontana, Javier Loricera, Ximena Elizabeth Larco Rojas, María-Luisa Peral
Publikováno v:
Abstracts accepted for Publication.
Background: Tofacitinib (TOFA) is the first inhibitor of JAK kinases with approval for the treatment of psoriatic arthritis (PsA) in Europe (July 2018)1. ToFA has shown efficacy in refractory patients to anti-TNF2. Objectives: A) to assess efficacy a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6bacfa1479a5769dfa23f37f5a822b1c
https://doi.org/10.1136/annrheumdis-2019-eular.7803
https://doi.org/10.1136/annrheumdis-2019-eular.7803
Autor:
María Caeiro, J. Pinto-Tasende, Rodrigo Aguirre, Alvaro Seijas, Francisco J. Blanco, Clara Ventin, Maria Teresa Silva
Publikováno v:
Abstracts accepted for Publication.
Background: Patients with psoriatic arthritis (PsA) show impact on physical and psychological aspect of the disease and it can be measured with the PsA Impact of Disease (PsAID) questionnaire. Impact of disease should improve if patient reach a minim
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6c86d701d7ba4562d4cdc0460657da41
https://doi.org/10.1136/annrheumdis-2019-eular.7393
https://doi.org/10.1136/annrheumdis-2019-eular.7393
Autor:
Ana Lois-Iglesias, Rodrigo Aguirre-del-Pino, Francisco Javier de-Toro-Santos, Clara Ventin-Rodriguez, Alvaro Seijas-Lopez, Maria Caeiro-Aguado
Publikováno v:
Poster Presentations.
Background: Musculoskeletal disorders cause in Spain 23% of temporary work disability (TD). They are the first cause of permanent work disability (PD). A study of early intervention by a rheumatologist reduced TD days reduced PD. Using the “Fit for
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::15b6fdf5a34dc7d2313eb24bbd1d7288
https://doi.org/10.1136/annrheumdis-2019-eular.4388
https://doi.org/10.1136/annrheumdis-2019-eular.4388
Autor:
José Luis Martín-Varillas, C. Y. Soleto, J. J. Alegre-Sancho, Josep Ramírez, Albert Mas, Mireia Moreno, L. Mendez Diaz, M. A. González-Gay, À. Martínez-Ferrer, Clara Ventin-Rodriguez, I. Gorostiza, Raquel Almodóvar, Olga Rusinovich, X. E. Larco Rojas, A. Crespo Golmar, Diana Prieto-Peña, E. Galindez, R. Garcia de Vicuna, Roman Blanco, B. Joven-Ibáñez, Mabel Moreno, F.M. Ortiz Sanjuan, Natalia Palmou-Fontana, Agusti Sellas-Fernández, M.C. Castro Villegas
Publikováno v:
Annals of the Rheumatic Diseases. 79:1682.1-1682
Background:Tofacitinib (TOFA) is the first JAKi approved for psoriatic arthritis (PsA) in Europe (July 2018). TOFA has shown efficacy in refractory patients to anti-TNF in Randomized Clinical Trials (RCT) (Gladman D. NEJM 2017; 377: 1525-36).Objectiv
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::defcfa4bb6fd0531b4f48e667e67664d
https://doi.org/10.1136/annrheumdis-2020-eular.2903
https://doi.org/10.1136/annrheumdis-2020-eular.2903
Publikováno v:
BMC Rheumatology, Vol 4, Iss 1, Pp 1-8 (2020)
Abstract Background Line blot immunoassays (LIA) for myositis-specific (MSA) and myositis-associated (MAA) autoantibodies have become commercially available. In the largest study of this kind, we evaluated the clinical performance of a widely used LI
Externí odkaz:
https://doaj.org/article/d0b74432da46461a845d2de664157ab4